| 1 | 10421617 | Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. | Drug Metab Dispos | 1999 Aug |
1 |
| 2 | 11596909 | Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC. | Clin Lab | 2001 |
2 |
| 3 | 12086554 | Kaletra (lopinavir/ritonavir). | Ann Pharmacother | 2002 Jul-Aug |
1 |
| 4 | 12372511 | Novel lopinavir analogues incorporating non-Aromatic P-1 side chains--synthesis and structure--activity relationships. | Bioorg Med Chem Lett | 2002 Nov 4 |
1 |
| 5 | 12458138 | Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. | Int J Antimicrob Agents | 2002 Dec |
1 |
| 6 | 12662125 | Lopinavir/ritonavir: a review of its use in the management of HIV infection. | Drugs | 2003 |
1 |
| 7 | 12700464 | Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. | AIDS | 2003 May 2 |
4 |
| 8 | 12705974 | Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry. | J Chromatogr B Analyt Technol Biomed Life Sci | 2003 May 25 |
1 |
| 9 | 12719666 | [First evaluations of LPV/RTV (Kaletra) efficacy on HIV-positive patients treated with multiple drugs]. | Infez Med | 2003 Mar |
1 |
| 10 | 12724045 | Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. | J Pharm Pharmacol | 2003 Mar |
6 |
| 11 | 12837856 | Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. | J Lipid Res | 2003 Oct |
1 |
| 12 | 12902797 | The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. | J Acquir Immune Defic Syndr | 2003 Aug 15 |
1 |
| 13 | 14525542 | Interleukin-7 levels may predict virological response in advanced HIV-1-infected patients receiving lopinavir/ritonavir-based therapy. | HIV Med | 2003 Oct |
1 |
| 14 | 14711599 | No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. | Eur J Med Res | 2003 Dec 9 |
2 |
| 15 | 14731164 | A prospective, controlled study assessing the effect of lopinavir on amprenavir concentrations boosted by ritonavir. | HIV Med | 2004 Jan |
2 |
| 16 | 15090838 | Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients. | AIDS | 2004 Jan 2 |
1 |
| 17 | 15222662 | Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir. | Pharmacotherapy | 2004 Jun |
1 |
| 18 | 15247556 | Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. | J Acquir Immune Defic Syndr | 2004 Aug 15 |
5 |
| 19 | 15254024 | Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen. | J Antimicrob Chemother | 2004 Aug |
3 |
| 20 | 15577646 | The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. | AIDS | 2004 Nov 5 |
4 |
| 21 | 15668539 | Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. | AIDS | 2005 Jan 28 |
1 |
| 22 | 15721475 | Blockade of HERG channels by HIV protease inhibitors. | Lancet | 2005 Feb 19-25 |
2 |
| 23 | 15764168 | Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen. | Scand J Infect Dis | 2004 |
1 |
| 24 | 15983895 | Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients. | HIV Clin Trials | 2005 Mar-Apr |
2 |
| 25 | 16143711 | Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. | J Antimicrob Chemother | 2005 Oct |
1 |
| 26 | 16163639 | Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. | Clin Infect Dis | 2005 Oct 15 |
1 |
| 27 | 16388722 | Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection. | Int J Immunopathol Pharmacol | 2005 Oct-Dec |
3 |
| 28 | 16639344 | Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. | J Acquir Immune Defic Syndr | 2006 May |
4 |
| 29 | 16910829 | Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. | AIDS Res Hum Retroviruses | 2006 Aug |
2 |
| 30 | 16934050 | The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects. | Br J Clin Pharmacol | 2006 Sep |
1 |
| 31 | 16954722 | Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. | AIDS | 2006 Sep 11 |
4 |
| 32 | 17202245 | Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. | J Antimicrob Chemother | 2007 Feb |
1 |
| 33 | 17310826 | Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. | Antivir Ther | 2006 |
2 |
| 34 | 17324111 | Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. | Pharmacogenomics | 2007 Mar |
1 |
| 35 | 17361129 | Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. | Clin Pharmacol Ther | 2007 Aug |
1 |
| 36 | 17451894 | Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor. | Int J Pharm | 2007 Jul 18 |
3 |
| 37 | 17503669 | Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. | Antivir Ther | 2007 |
1 |
| 38 | 17591027 | Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir. | Antivir Ther | 2007 |
3 |
| 39 | 17664327 | Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. | Antimicrob Agents Chemother | 2007 Oct |
1 |
| 40 | 17668557 | Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. | Antivir Ther | 2007 |
1 |
| 41 | 17683706 | [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir]. | Med Clin (Barc) | 2007 Jul 14 |
2 |
| 42 | 17713471 | Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma. | Clin Pharmacol Ther | 2008 Apr |
1 |
| 43 | 17890284 | Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. | J Antimicrob Chemother | 2007 Nov |
4 |
| 44 | 18090045 | Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. | AIDS | 2007 Oct 18 |
2 |
| 45 | 18090297 | Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity. | AIDS | 2007 Nov 12 |
1 |
| 46 | 18183034 | Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. | Clin Pharmacol Ther | 2008 Jul |
8 |
| 47 | 18230615 | A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells. | J Biol Chem | 2008 Apr 11 |
2 |
| 48 | 18356150 | First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. | J Antimicrob Chemother | 2008 Jun |
1 |
| 49 | 18455890 | Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor. | Int J Pharm | 2008 Jul 9 |
6 |
| 50 | 18576910 | Possible antiretroviral therapy-warfarin drug interaction. | Pharmacotherapy | 2008 Jul |
1 |